tucatinib Report issue

Small molecule Orphan Drug FDA Approved FDA Fast Track FDA Breakthrough Therapy FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Tucatinib, sold under the brand name Tukysa, is a small molecule inhibitor of HER2 for the treatment of HER2-positive breast cancer. It was developed by Array BioPharma and licensed to Cascadian Therapeutics.   Wikipedia

  • SMILES: Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc5ccn6ncnc6c5
  • InChIKey: SDEAXTCZPQIFQM-UHFFFAOYSA-N
  • Mol. Mass: 480.53
  • ALogP: 5.09
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

United States

$57.7530 - $148.7438
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

tucatinib

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue